---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000047"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-07-22T23:59:59+00:00"
generated_at: "2026-05-18T04:30:06.546759+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma appoints James A. Schoeneck to board of directors

## Summary
- Board size increased from six to seven; Schoeneck appointed effective July 22, 2025.
- Schoeneck is former CEO of Depomed (2011-2017) and BrainCells (2005-2011).
- Currently serves as independent director and chairman at FibroGen and Calidi Biotherapeutics.
- Board determined Schoeneck is independent under Nasdaq rules.

## SEC filing metadata
- accession: 0001835268-25-000047
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-07-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000047/0001835268-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000047/cntb-20250722.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000047
- JSON: https://secwatch.observer/filing/0001835268-25-000047.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.